While it has seen no coronavirus-related business impact so far and uncertainties remain, Takeda expects lower costs related to the Shire acquisition to propel its profits this fiscal year.
Takeda Pharmaceutical Co. Ltd. said in reporting its annual figures that it has to date not experienced any material impact on its financial results from the global coronavirus pandemic, despite various changes to its operations and working practices in line with the broader responses around the world.
Based on current information, Japan’s leading pharma company said it believes that its performance in the current fiscal year (ending 31 March 2021) “will not be materially affected.” But it...
Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.
Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.
The UK major's asthma drug gets a key expanded approval.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
